CN111166745A - Composition containing racemic oxypyramine or salt thereof and application - Google Patents
Composition containing racemic oxypyramine or salt thereof and application Download PDFInfo
- Publication number
- CN111166745A CN111166745A CN202010058985.9A CN202010058985A CN111166745A CN 111166745 A CN111166745 A CN 111166745A CN 202010058985 A CN202010058985 A CN 202010058985A CN 111166745 A CN111166745 A CN 111166745A
- Authority
- CN
- China
- Prior art keywords
- salt
- formula
- compound
- racemic
- iib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
The invention discloses a composition containing racemic oxypyramine or salt thereof and application thereof, belonging to the technical field of medicines. The invention relates to a pharmaceutical composition, which contains racemic oxypyramine shown in formula I or salt thereof, and one or two compounds shown in formula IIA and formula IIB or salt thereof,
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a composition containing racemic oxypyramine or salt thereof and application thereof.
Background
Clopidogrel (Clopidogrel) is a thienopyridine derivative, which is an inactive prodrug, and the absorption of the protodrug in the small intestine is regulated by a proton pump P glycoprotein encoded by the ABCB1 gene, wherein 85% of the protodrug is excreted to the outside of the body through the intestinal tract by being converted into an inactive carboxylic acid derivative by carboxylesterase (CES1), 15% of the Clopidogrel enters the blood circulation and is metabolized into oxigrelide under the action of a liver cytochrome P450 enzyme system, and further oxidized into an active thiol derivative of Clopidogrel (R-130964. the metabolism thereof is divided into two stages, namely, the first stage in which Clopidogrel is metabolized into inactive 2-oxy-Clopidogrel by CYP1A2 (about 36%), CYP2B6 (about 19%), Clopidogrel 2C19 (about 45%), and the second stage in which 2-oxy-Clopidogrel is further metabolized into an active thiol derivative (R-130964).
Because clopidogrel is a prodrug and is metabolized in vivo through two steps of liver CYP450 enzymes to generate active metabolites, wherein CYP2C19 plays an important role in the two-step oxidation of clopidogrel, the genetic metabolic difference of CYP2C19 enzymes causes the clopidogrel to have larger individual difference on the clinical treatment effect, about 4-30% of patients have the phenomenon of clopidogrel resistance, and the risks of death, myocardial infarction and thrombosis in a stent are increased. And individual differences can be reduced by administering 2-oxo-clopidogrel (a compound of formula I).
The clopidogrel resistance phenomenon caused by CYP2C19 enzyme gene polymorphism is reduced in clinic, the drug interaction is reduced, the generation of a large amount of potentially toxic clopidogrel acid is avoided, the clinical safety is improved, and the urgent clinical requirements are met.
Patent CN104245707A discloses a preparation method of 2-oxo-clopidogrel (compound of formula I) and its related map, and on this basis, patent CN104245707A also discloses a substantially pure optical isomer as a preferred antithrombotic agent.
However, for 2-oxo-clopidogrel (compound of formula I), no other impurities were deeply controlled.
Disclosure of Invention
In subsequent researches on 2-oxo-clopidogrel (a compound shown in a formula I), the inventor of the invention surprisingly discovers that the raw material of the 2-oxo-clopidogrel is inevitably oxidized to generate a plurality of oxidation impurities in the processes of placing and researching preparations, wherein the impurities are one or two of impurities shown in a formula IIA and a formula IIB. Animal tests show that the impurities exceed certain limits and generate digestive tract toxicity, so that the content of the impurities in the raw materials and the preparation must be strictly controlled and meets the requirement of medicinal use.
An object of the present invention is to provide a composition containing racemic oxypyramine or a salt thereof.
The invention also aims to provide the application of the composition.
The technical scheme adopted by the invention is as follows:
the invention relates to a pharmaceutical composition, which contains racemic oxypyramine shown in formula I or salt thereof, and one or two compounds shown in formula IIA and formula IIB or salt thereof,
in the technical scheme of the invention, the composition contains more than 85% of racemic oxypyramine shown in formula I or salt thereof;
preferably, the composition contains more than 95% of the racemic oxypyramine shown in the formula I or the salt thereof;
more preferably, the composition contains more than 98% of the racemic oxypyramine shown in the formula I or the salt thereof.
In the embodiment of the invention, the individual content or the cumulative content of one or two compounds of the formula IIA and the formula IIB or the salt thereof is less than 3.0 percent;
preferably, the individual or cumulative amount of one or both compounds of formula IIA, formula IIB or salts thereof is less than 1.0%;
more preferably, the individual or cumulative amount of one or both compounds of formula IIA, IIB or salts thereof is less than 0.5%.
In the technical scheme of the invention, the salt comprises sulfate, bisulfate, hydrochloride, hydrobromide, benzene sulfonate, maleate, fumarate, methanesulfonate, succinate, phosphate, tartrate or oxalate;
preferably, a hydrogen sulfate salt, a hydrogen bromide salt, a hydrochloride salt, a maleate salt, a fumarate salt, a benzenesulfonate salt, an oxalate salt or a methanesulfonate salt is included.
The invention provides a pharmaceutical preparation, which comprises the pharmaceutical composition and one or more pharmaceutically acceptable carriers.
The "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic agent is administered and which is, within the scope of sound medical judgment, suitable for contact with the tissues of humans and/or other animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio.
The invention also provides application of the pharmaceutical composition in preparing a medicament for preventing or treating the antithrombotic.
Preferably, the antithrombotic agent includes an agent for preventing or treating atherosclerotic diseases, myocardial infarction, stroke, ischemic cerebral thrombosis, peripheral arterial diseases, acute coronary syndrome, or thrombosis after coronary intervention.
Finally, based on the high-purity 2-oxo-clopidogrel obtained for the first time, the invention also provides the application of the composition in the quality detection of antithrombotic drugs, namely antithrombotic drugs taking 2-oxo-clopidogrel as the main active component, wherein the application comprises the application as a standard reference substance.
Unless otherwise specified, the purity or content in the present invention expressed as a percentage means a mass percentage.
Compared with the prior art, the invention has the following beneficial effects:
the invention discovers the oxidation impurities generated in the process of placing or preparing the active ingredient of the oxy-clopidogrel for the first time; and controls toxic impurities, and provides the 2-oxo-clopidogrel composition meeting the medicinal requirements.
Drawings
FIG. 1 is a NOE plot of a compound of the present invention of formula IIA;
FIG. 2 is a NOE plot of a compound of the present invention of formula IIB.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are provided for illustration only and are not intended to limit the scope of the present invention, and any equivalent replacement in the field made in the light of the present disclosure is included in the scope of the present invention.
The structure of the compounds of the examples is by Mass Spectrometry (MS) or nuclear magnetic resonance (1HNMR) device to determine:
nuclear magnetic resonance (1HNMR) displacement (δ) is given in units of parts per million (ppm); nuclear magnetic resonance (1HNMR) was determined using a Bruker AVANCE-300 nuclear magnetic spectrometer with internal standard of Tetramethylsilane (TMS) and chemical shifts of 10-6(ppm) is given as a unit.
Mass Spectrometry (MS) measurements were carried out using a FINNIGAN LCQAD (ESI) mass spectrometer (manufacturer: Therm, model: Finnigan LCQ advantage MAX).
The thin layer silica gel is prepared from HSGF254 or GF254 silica gel plate of Taiwan yellow sea, and the column chromatography is carried by silica gel 200-300 mesh.
The starting materials and reagents for the examples are all commercially available.
The solution mentioned in the reaction of the present invention is an aqueous solution in the case where no specific explanation is given to the present invention, and the term "room temperature" means between 10 ℃ and 25 ℃.
Preparation example 1
The preparation example discloses a preparation method of a compound shown as a formula IIA, which comprises the following steps:
synthesis of methyl (S) -2- (2-chlorophenyl) -2- ((S) -7 a-hydroxy-2-oxo-2, 6,7,7 a-tetrahydrothieno [3,2-c ] pyridine-5 (4H) acetate
the reaction mixture was slowly poured into 586mL of anhydrous THF containing 58.6gSM1 dissolved therein at room temperatureA suspension of 7.1g sodium hydride in 35mL of anhydrous THF was added dropwise thereto, followed by stirring for 30min, followed by slow addition of 69.2g SM2 in 70mL of anhydrous THF and stirring at room temperature for 12h, and TLC iodine was used to monitor the reaction. After completion of the reaction, 650mL of saturated brine was added, and the mixture was extracted with 1500mL of DCM. The organic layer is coated with Na2SO4Dried and the solvent evaporated under reduced pressure. The residue was purified on a silica gel column to give IM1 as a colorless oily liquid 52.3g (yield 62.3%) (PE/EA ═ 20/1 to 5/1). LC-MS (ESI) [ M + H ]+]+＝286.5(M+H+) Consistent with the structure.
a suspension of 7.2g sodium hydride in 36mL of extra dry THF was slowly added dropwise to 861mL of extra dry THF containing 86.1g IM1 in an ethanol bath at-45 ℃ and stirred vigorously for 30min, 200mL of LDA was slowly added dropwise first, followed by slow addition of 241mL of THF containing 48.2g liquid bromine for further low temperature reaction for 3h, with TLC iodine being used to monitor the reaction. After the reaction, the temperature is slowly raised to the room temperature, 30.5g of triethylamine is slowly added, the mixture is stirred for 5 hours at the room temperature, and TLC iodine is used for detecting and controlling the reaction. The solvent was removed by evaporation under reduced pressure. The residue was purified on a silica gel column. 28.3g (yield 32.9%) of IM2 was obtained as a colorless oily liquid (PE/EA: 15/1 to 5/1). LC-MS (ESI) [ M + H ]+]+＝284.5(M+H+) Consistent with the structure.
to 203mL of anhydrous THF in which 20.3g of IM2 was dissolved was added 6.03g of NaHS under nitrogen protection at room temperature, and reacted for 12h under nitrogen protection. The reaction was filtered, the solvent removed by evaporation under reduced pressure from the organic phase, and the residue was purified on a basic alumina column to give IM3 as an off-white pasty solid 3.81g (19.6% yield) (DCM/MeOH ═ 15/1 to 8/1). LC-MS (ESI) [ M + H ]+]+＝272.5(M+H+) Consistent with the structure.
Step 4 Synthesis of racemic IM4
To 73mL of DMC in which 3.64g of IM3 was dissolved, 6.7mL of 4M hydrochloric acid was slowly added dropwise over 30min in an ice bath at 0 ℃ under nitrogen, and the reaction was monitored by TLC iodine. After the reaction is finished, liquid is separated, and the organic layer is added with Na2SO4Dried and the solvent evaporated under reduced pressure. The residue was purified on basic alumina column. This gave 0.61g (26.5% yield) of a pale yellow oily liquid (DCM/MeOH-15/1 to 8/1). LC-MS (ESI) [ M + H ]+]+＝172.4(M+H+) Consistent with the structure.
To a solution of 0.57g IM4 in 11.4mL acetonitrile at 50 deg.C under nitrogen, 0.88g SM3 and 0.46g anhydrous potassium carbonate were added and the reaction was stirred for 3 h. The reaction was monitored by TLC UV 254 nm. After the reaction was completed, the solvent was evaporated under reduced pressure. The residue was purified on basic alumina column. This gave 0.52g (yield 44.1%) of a pale yellow pasty solid (PE/EA: 10/1 to 3/1) LC-MS (ESI) [ M + H ]+]+＝354.9(M+H+) Consistent with the structure.
0.52g of the obtained racemic product was passed through a medium pressure to prepare a chiral column (xylonite)
IA) to give the two corresponding chiral isomers, wherein the amount of formula IIA is 0.25 g. LC-MS (ESI) [ M + H ]+]+＝354.9(M+H+)；1H-NMR(400MHz,d6-DMSO):7.62-7.54(m,2H),7.44-7.25(m,2H),6.03(d,1H),4.86(d,1H),4.63(br,1H),3.68(d,3H),3.10(m,1H),3.00(m,1H),2.44-2.36(m,2H),2.00-1.84(m,1H),1.72-1.61(m,1H) are consistent with the structure, and the chirality is shown in NOE spectrum.
Preparation example 2
The preparation example discloses a preparation method of a formula IIB, which specifically comprises the following steps:
synthesis of methyl N-oxide- (S) -2- (2-chlorophenyl) -2- ((S) -2-oxo-2, 6,7,7 a-tetrahydrothieno [3,2-c ] pyrid-5 (4H) -yl) acetate.
Referring to patent CN104245707A, after the structure of the compound with the structure SMX is synthesized, 4.6g of the obtained racemic product SMX is resolved by a preparative chiral column to obtain two relatively pure corresponding chiral isomers SMX-1 and SMX-2. 1.24g of SMX-1 and 1.51g of SMX-2. (yield 59.8%) LC-MS (ESI) [ M + H ]+]+＝338.8(M+H+) Consistent with the structure.
putting 1.24g of SMX-1 and 10mL of glacial acetic acid into a 50mL three-neck bottle at room temperature, dropwise adding 1mL of hydrogen peroxide under ice bath, heating to 80 ℃ after dropwise adding, reacting for 2H, monitoring by TLC (developing agent: ethyl acetate/petroleum ether is 1/3, developing under 254nm ultraviolet lamp), concentrating dry acetic acid under reduced pressure after the raw material reaction is finished, adjusting pH to 8-9 with saturated sodium carbonate, extracting with dichloromethane by 10mL, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure at 30 ℃ to obtain 0.81g of target product, obtaining yield of 62.5%, and LC-MS (ESI) [ M + H ] (M + H)+]+＝354.8(M+H+) 1H-NMR (400MHz, CDCl3):7.5(m,1H),7.39(m,1H),7.27(m,1H),7.27(m,1H),5.98(s,1H),4.88(s,1H),4.15(d,1H),3.23-3.89(d,2H),3.69(s,3H),2.58-2.99(d,2H),1.82-2.32(m,2H) was consistent with the structure, and the chirality was shown in the NOE diagram.
Example 1
This example discloses a composition containing 4% of a compound of formula IIA.
The racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A had a purity of 98.0% (nitrogen blanket, no impurity-containing compound of formula iia or formula iib). To 0.96g of 2-oxo-clopidogrel was added 0.04g of a compound of formula IIA with a purity of 98.0% and mixed uniformly to obtain a composition containing 4% of the compound of formula IIA.
Example 2
This example discloses compositions containing 3% of a compound of formula IIA.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (protected with nitrogen and containing no impurity compound of formula IIA or formula IIB), was added to 0.97g of 2-oxo-clopidogrel, 0.03g of compound of formula IIA having a purity of 98.0%, and mixed uniformly, thereby obtaining a composition having a compound of formula IIA content of 3%.
Example 3
This example discloses a composition containing 1% of a compound of formula IIA.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A and having a purity of 98.0% (nitrogen blanket, containing no impurity compound of formula IIA or formula IIB) was added to 0.99g of 2-oxo-clopidogrel and mixed well with 0.01g of compound of formula IIA having a purity of 98.0%, thereby obtaining a composition disclosed in this example as having a compound of formula IIA content of 1%
Example 4
This example discloses compositions containing 0.5% of a compound of formula IIA.
Racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (protected with nitrogen, containing no impurity compound of formula IIA or formula IIB), to 0.995g of 2-oxo-clopidogrel was added 0.005g (purity of 98.0%) of compound of formula IIA, and mixed well, thereby obtaining a composition containing 0.5% of compound of formula IIA
Example 5
This example discloses compositions containing 4% of a compound of formula IIB.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (protected with nitrogen and containing no impurity compound of formula IIA or formula IIB), was added to 0.96g of 2-oxo-clopidogrel, 0.04g of compound of formula IIB having a purity of 98.0%, and mixed uniformly, thereby obtaining a composition having a compound of formula IIB content of 4%.
Example 6
This example discloses compositions containing 3% of a compound of formula IIB.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (nitrogen protection, containing no impurity compound of formula IIA or formula IIB), was added to 0.97g of 2-oxo-clopidogrel with 0.03g (purity of 98.0%) of the compound of formula IIB, and mixed uniformly, thereby obtaining a composition having a compound of formula IIB content of 3%.
Example 7
This example discloses a composition containing 1% of a compound of formula IIB.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (nitrogen protection, containing no impurity compound of formula IIA or formula IIB), was added to 0.99g of 2-oxo-clopidogrel with 0.01g (purity of 98.0%) of the compound of formula IIB, and mixed uniformly, thereby obtaining a composition having a compound of formula IIB content of 1%.
Example 8
This example discloses compositions containing 0.5% of a compound of formula IIB.
2-oxo-clopidogrel (compound of formula I), a racemic compound synthesized according to CN104245707A, having a purity of 98.0% (nitrogen blanket, containing no impurity compound of formula IIA or formula IIB), was added to 0.995g of 2-oxo-clopidogrel with 0.005g (purity of 98.0%) of the compound of formula IIB and mixed well, thereby obtaining a composition having a compound of formula IIB content of 0.5%.
Example 9
This example discloses a composition of 4% total compound of formula IIA and formula IIB.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (under nitrogen protection and containing no impurity compound of formula IIA or formula IIB), was added to 0.96g of 2-oxo-clopidogrel, 0.020g (purity 98.0%) of the compound of formula IIA, and 0.020g (purity 98.0%) of the compound of formula IIB were added and mixed uniformly, thereby obtaining a composition in which the total amount of the compounds of formula IIA and formula IIB was 4%.
Example 10
This example discloses compositions of formula IIA and formula IIB in a total amount of 3%.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (nitrogen blanket, containing no impurity compound of formula IIA or formula IIB), was added to 0.97g of 2-oxo-clopidogrel, 0.015g (purity 98.0%) of the compound of formula IIA was added, 0.015g (purity 98.0%) of the compound of formula IIB was added, and the mixture was mixed well, thereby obtaining a composition in which the total amount of the compounds of formula IIA and formula IIB was 3%
Example 11
This example discloses a composition of 1% total compound of formula IIA, formula IIB.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (nitrogen protection, containing no impurity compound of formula IIA or formula IIB), was added to 0.99g of 2-oxo-clopidogrel, 0.005g (purity 98.0%) of the compound IIA, and 0.005g (purity 98.0%) of the compound IIB, and mixed uniformly, thereby obtaining a composition having a total content of 1% of the compounds of formula IIA and formula IIB.
Example 12
This example discloses a composition of 0.5% total compound of formula IIA, formula IIB.
A racemic compound 2-oxo-clopidogrel (compound of formula I) synthesized according to CN104245707A, having a purity of 98.0% (under nitrogen protection and containing no impurity compound of formula IIA or formula IIB), was added to 0.995g of 2-oxo-clopidogrel, 0.0025g (purity 98.0%) of the compound IIA, and 0.0025g (purity 98.0%) of the compound IIB, and mixed uniformly, thereby obtaining a composition having a total content of the compounds of formula IIA and formula IIB of 0.5%.
Test example 1 Effect of continuous administration of drugs into rat body on digestive tract
1. Purpose of the experiment
The influence of the drug on the digestive tract of rats after continuous gavage administration for 21 days in rats at equimolar dose was examined.
2. Materials and methods
2.1 test substance
Compositions prepared according to the methods of examples 1-12;
2-oxo-clopidogrel (compound of formula I), purity 98.0%, (nitrogen protection, no impurity compound of formula IIA or formula IIB).
2.2 preparation of the drug delivery preparation
Accurately weighing the tested compound in a clean administration container respectively, adding a proper amount of Solutol for dissolving, carrying out spiral oscillation, adding pure water, carrying out ultrasound, and carrying out spiral oscillation until the compound is completely dissolved; the dosing formulations were all freshly prepared on the day of dosing.
2.3 test grouping and administration
TABLE 1 multiple gavage dosing regimen for the compounds
2.4 test methods:
the experimental method comprises the following steps: the SD rats are male and female simultaneously and are randomly grouped into 10 rats each group; the corresponding drug or normal saline is administrated by gavage once a day for 21 consecutive days, the excrement characters of each group of animals are observed after the gavage administration on the 21 st day, and the influence of the drug on the digestive tract of the rat is researched after the drug is administrated for 21 consecutive days.
3. Test results
The results show that after 21 days of continuous gavage administration of the composition of each example of the present invention to rats, 6/10 and 7/10 rats in the groups of example 1, example 5 and example 9 respectively have soft stools or loose stools, which are significantly different from those in the group of 2-oxo-clopidogrel administration (P < 0.05); the rats in the remaining examples did not show soft or loose stools (0/10), indicating that compositions containing more than 3% of impurities of either or both of formula IIA and formula IIB, when administered by continuous gavage, all produced gastrointestinal toxicity.
TABLE 2 Effect on the behaviour of rat excreta
Note: p <0.05vs 2-oxo-clopidogrel group
The above-mentioned embodiment is only one of the preferred embodiments of the present invention, and should not be used to limit the scope of the present invention, but all the insubstantial modifications or changes made within the spirit and scope of the main design of the present invention, which still solve the technical problems consistent with the present invention, should be included in the scope of the present invention.
Claims (8)
1. A pharmaceutical composition is characterized by comprising racemic oxypyramine shown in formula I or salt thereof, and a compound containing one or two of formula IIA and formula IIB or salt thereof,
2. the pharmaceutical composition of claim 1, wherein the composition comprises more than 85% of racemic oxypyramine represented by formula I or a salt thereof;
preferably, the composition contains more than 95% of the racemic oxypyramine shown in the formula I or the salt thereof;
more preferably, the composition contains more than 98% of the racemic oxypyramine shown in the formula I or the salt thereof.
3. The pharmaceutical composition of claim 1 or 2, wherein the individual or cumulative amount of one or both of the compounds of formula IIA, formula IIB or salts thereof is less than 3.0%;
preferably, the individual or cumulative amount of one or both of said compounds of formula IIA, IIB or salts thereof is less than 1.0%;
more preferably, the individual or cumulative amount of one or both of the compounds of formula IIA, IIB or salts thereof is less than 0.5%.
4. The pharmaceutical composition of claim 1 or 2, wherein the salt comprises a sulfate, bisulfate, hydrochloride, hydrobromide, besylate, maleate, fumarate, mesylate, succinate, phosphate, tartrate or oxalate salt;
preferably, the salt comprises a hydrogen sulfate salt, a hydrobromide salt, a hydrochloride salt, a maleate salt, a fumarate salt, a benzenesulfonate salt, an oxalate salt or a methanesulfonate salt.
5. A pharmaceutical formulation comprising a pharmaceutical composition according to any one of claims 1 to 5 and one or more pharmaceutically acceptable carriers.
6. Use of the pharmaceutical composition according to any one of claims 1 to 4 for the preparation of a medicament for the prophylaxis or treatment of thrombosis.
7. The use according to claim 6, wherein the antithrombotic agent comprises an agent for preventing or treating atherosclerotic diseases, myocardial infarction, stroke, ischemic cerebral thrombosis, peripheral arterial diseases, acute coronary syndromes or thrombosis after coronary intervention.
8. Use of the pharmaceutical composition according to any one of claims 1 to 4 for the quality testing of antithrombotic drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010058985.9A CN111166745A (en) | 2020-01-19 | 2020-01-19 | Composition containing racemic oxypyramine or salt thereof and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010058985.9A CN111166745A (en) | 2020-01-19 | 2020-01-19 | Composition containing racemic oxypyramine or salt thereof and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111166745A true CN111166745A (en) | 2020-05-19 |
Family
ID=70620578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010058985.9A Pending CN111166745A (en) | 2020-01-19 | 2020-01-19 | Composition containing racemic oxypyramine or salt thereof and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111166745A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115429797A (en) * | 2022-08-31 | 2022-12-06 | 成都施贝康生物医药科技有限公司 | Composition containing oxygen clopidogrel or salts thereof and preparation thereof |
| WO2023241688A1 (en) * | 2022-06-17 | 2023-12-21 | 成都施贝康生物医药科技有限公司 | Pharmaceutical composition for treating and resisting blood coagulation and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070044323A (en) * | 2005-10-24 | 2007-04-27 | 에스케이케미칼주식회사 | Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate |
| WO2009077797A1 (en) * | 2007-12-14 | 2009-06-25 | Richter Gedeon Nyrt. | Racemization process for the preparation of an intermediate of clopidogrel hydrogen sulphate |
| CN106467546A (en) * | 2015-08-22 | 2017-03-01 | 陕西合成药业股份有限公司 | Clopidogrel derivant and its production and use |
| CN108685913A (en) * | 2018-07-31 | 2018-10-23 | 成都施贝康生物医药科技有限公司 | The composition and preparation method and application of oxygen-containing pyrrole Gray optical isomer or its salt |
-
2020
- 2020-01-19 CN CN202010058985.9A patent/CN111166745A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070044323A (en) * | 2005-10-24 | 2007-04-27 | 에스케이케미칼주식회사 | Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate |
| WO2009077797A1 (en) * | 2007-12-14 | 2009-06-25 | Richter Gedeon Nyrt. | Racemization process for the preparation of an intermediate of clopidogrel hydrogen sulphate |
| CN106467546A (en) * | 2015-08-22 | 2017-03-01 | 陕西合成药业股份有限公司 | Clopidogrel derivant and its production and use |
| CN108685913A (en) * | 2018-07-31 | 2018-10-23 | 成都施贝康生物医药科技有限公司 | The composition and preparation method and application of oxygen-containing pyrrole Gray optical isomer or its salt |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023241688A1 (en) * | 2022-06-17 | 2023-12-21 | 成都施贝康生物医药科技有限公司 | Pharmaceutical composition for treating and resisting blood coagulation and use thereof |
| CN115429797A (en) * | 2022-08-31 | 2022-12-06 | 成都施贝康生物医药科技有限公司 | Composition containing oxygen clopidogrel or salts thereof and preparation thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2527917B2 (en) | Remedy | |
| JP5596680B2 (en) | Oral anticancer drug | |
| JP2001515516A (en) | Use of colhinol derivatives as vascular damaging agents | |
| CA2055859A1 (en) | Oxazolopyridine derivatives; process for preparing the same and pharmaceutical compositions containing them | |
| JP2012509351A (en) | Fluorination of organic compounds | |
| WO2013028495A1 (en) | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma | |
| EP2687531B1 (en) | Tetrahydrocarboline derivative | |
| EP3858814A1 (en) | Nitroxoline prodrug and use thereof | |
| WO2023061095A1 (en) | 14-CHLORO-β-ELEMENE NITRIC OXIDE DONOR TYPE DERIVATIVE, PREPARATION AND APPLICATION THEREOF | |
| CN111166745A (en) | Composition containing racemic oxypyramine or salt thereof and application | |
| NO331505B1 (en) | (-) The enantiomer of tenatoprazole, a pharmaceutical composition containing it and its use for the preparation of a medical preparation for the treatment of disease | |
| CN111150731A (en) | Composition containing oxirangol optical isomer or salt thereof and application | |
| JP2010505747A (en) | Selective antagonist of A2A adenosine receptor | |
| WO2020156189A1 (en) | Camptothecin derivative and water-soluble prodrug thereof, pharmaceutical composition containing same, preparation method, and use | |
| CN1944448B (en) | Puerarin derivative and its medicinal use | |
| CN114948953A (en) | Heteroatom substituted aromatic compound and application of salt thereof | |
| NZ577311A (en) | The oxalate salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one | |
| EP1132383B1 (en) | Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine | |
| WO2019232662A1 (en) | Indolizine compound having anticancer activity and derivative thereof | |
| JP5888612B2 (en) | Crystals of condensed pyridine compound salts | |
| CN110372614B (en) | Tetrahydroquinoxaline compound, preparation method and application thereof | |
| CN111138450B (en) | Anti-inflammatory compound and preparation method and application thereof | |
| CN101787029A (en) | Long-chain alkyl coptisine halate derivative, synthesis method and application | |
| CN106478616B (en) | Crystalline form of GPR40 agonist and preparation method thereof | |
| JPS6241234B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 610000 No. 1, floor 1, unit 1, building 26, No. 2, Tianyu Road, high tech Zone, Chengdu, Sichuan Applicant after: CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECHNOLOGY Co.,Ltd. Address before: No.1, 2nd floor, building 1, No.17 Xixin Avenue, high tech Zone, Chengdu, Sichuan 610000 Applicant before: CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECHNOLOGY Co.,Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |